Constitutional symptoms (fatigue, lymphadenopathy, and weight loss) are not included in the SLE disease activity index-2000 (SLEDAI-2K). In this pilot study, we assessed the concurrent and construct validity of a revised SLEDAI-2K (SLED-R) that included these symptoms with the original SLEDAI-2K (SLED-O), using the physician global assessment of disease activity (PGA) as the reference.
Methods
Our revised SLED-R substituted the SLED-O’s fever descriptor with a constitutional descriptor that included fever, fatigue, lymphadenopathy, and/or weight loss. SLED-O, SLED-R, PGA and patient global assessment (PtGA) scores were collected prospectively. Bland-Altman correlations for repeated measures were calculated and Meng’s z-test was used to compare correlations between dependent and overlapping correlation coefficients. Associations between constitutional symptoms and disease activity measures were analyzed using Mann-Whitney U, Kruskal-Wallis, Chi-square tests and repeated measures correlations.
Results
1123 SLED-O, SLED-R, PGA, and 1066 PtGA were collected in 239 subjects. The new descriptor was scored in 45 subjects (18.8%) and 92 instances (8.1%), while the original descriptor, fever, was scored in only 4 subjects (1.7%) and 5 instances (0.4%). Mean SLED-O, PGA and PtGA scores were higher when the constitutional descriptor was scored versus not (p < .001). The correlation between SLED-R and PGA was marginally higher than between SLED-O and PGA (p < .001). Fatigue contributed most to this increase (p = .001) and associated with both higher PGA and PtGA scores (p < .001). Mean SLED-O and PGA scores were higher when ≥1 constitutional symptom(s) were scored versus not (p < .002). Correlations between PGA and PtGA when the new descriptor was scored versus not were similar (p = .860). The frequency of concordance between PGA and PtGA was lower when the new descriptor was scored (55%) versus not (72.5%), with PGA > PtGA when the new descriptor was scored (p < .001).
Conclusion
The addition of constitutional symptoms to SLEDAI-2K, particularly fatigue, resulted in a marginal increase in its correlation with PGA, and new constitutional symptoms associated with higher SLED-O and PGA scores. As fatigue is subjective and difficult to attribute to SLE, its validity and inter-rater reliability in scoring remains uncertain. The clinical utility of SLED-R remains unclear, and further studies of its validity and reliability are needed.
MikdashiJNivedO. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther2015; 17: 183.
2.
FiresteinGSBuddRCGabrielSE, et al.Systemic lupus erythematosus and related syndromes. In: FiresteinGSBuddRCGabrielSE, et al. (eds). Kelley and firestein’s textbook of rheumatology. 10th ed.Amsterdam, The Netherland: Elsevier, 2017.
3.
ShapiraYWeinbergerAWysenbeekAJ. Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations. Clin Rheumatol1996; 15: 335–338.
4.
AfzalWArabTUllahT, et al.Generalized lymphadenopathy as presenting feature of systemic lupus erythematosus: case report and review of the literature. J Clin Med Res2016; 8: 819–823.
5.
CalguneriMOzturkMAOzbalkanZ, et al.Frequency of lymphadenopathy in rheumatoid arthritis and systemic lupus erythematosus. J Int Med Res2003; 31: 345–349.
6.
StojanGLiJWittmaackA, et al.Cachexia in systemic lupus erythematosus: risk factors and relation to disease activity and damage. Arthritis Care Res2021; 73: 1577–1582.
7.
Hinojosa-AzaolaASánchez-GuerreroJ. Overview and clinical presentation. In: Dubois’ lupus erythematosus and related syndromes. 9th ed.New York, NY: Elsevier, 2019, pp. 389–394.
8.
DuboisELTuffanelliDL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA1964; 190: 104–111.
9.
BaracosVEMartinLKorcM, et al.Cancer-associated cachexia. Nat Rev Dis Prim2018; 4: 17105.
10.
Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum. 2007; 57: 1348–1357.
11.
Lupus and Allied Diseases Association, Lupus Foundation of America, Lupus Research Alliance. Lupus: patient voices. Report on externally-led patient-focused drug development meeting: September 25, 2017. 2018. URL:http://www.nolupus.org/LupusPatientVoicesFINAL.pdf
12.
Zonana-NacachARosemanJMMcGwinGJr., et al.Systemic lupus erythematosus in three ethnic groups. Vi: factors associated with fatigue within 5 years of criteria diagnosis. Lumina study group. Lupus in minority populations: nature vs nurture. Lupus2000; 9: 101–109.
13.
TenchCMMcCurdieIWhitePD, et al.The prevalence and associations of fatigue in systemic lupus erythematosus. Rheumatology2000; 39: 1249–1254.
14.
PisetskyDSClowseMEBCriscione-SchreiberLG, et al.A novel system to categorize the symptoms of systemic lupus erythematosus. Arthritis Care Res2019; 71: 735–741.
15.
DaviesKDuresENgWF. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol2021; 17: 651–664.
16.
MackayM. Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus. Immunol Res2015; 63: 26–37.
17.
KatzPPAndrewsJYazdanyJ, et al.Is frailty a relevant concept in sle?Lupus science & medicine2017; 4: e000186.
18.
LeggeAKirklandSRockwoodK, et al.Construction of a frailty index as a novel health measure in systemic lupus erythematosus. J Rheumatol2020; 47: 72–81.
19.
TimlinHSyedAHaqueU, et al.Fevers in adult lupus patients. Cureus2018; 10: e2098.
20.
MoscaMCostenbaderKHJohnsonSR, et al.Brief report: how do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classification criteria. Arthritis Rheumatol2019; 71: 91–98.
21.
LeuchtenNMilkeBWinkler-RohlfingB, et al.Early symptoms of systemic lupus erythematosus (sle) recalled by 339 sle patients. Lupus2018; 27: 1431–1436.
22.
BombardierCGladmanDDUrowitzMB, et al.Derivation of the sledai. A disease activity index for lupus patients. The committee on prognosis studies in sle. Arthritis Rheum1992; 35: 630–640.
PetriMGenoveseMEngleE, et al.Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum1991; 34: 937–944.
25.
ChessaEPigaMFlorisA, et al.Use of physician global assessment in systemic lupus erythematosus: a systematic review of its psychometric properties. Rheumatology2020; 59: 3622–3632.
26.
AranowCAskanaseAOonS, et al.Laboratory investigation results influence physician's global assessment (pga) of disease activity in sle. Ann Rheum Dis2020; 79: 787–792.
FranklynKLauCSNavarraSV, et al.Definition and initial validation of a lupus low disease activity state (lldas). Ann Rheum Dis2016; 75: 1615–1621.
29.
van VollenhovenRFBertsiasGDoriaA, et al.2021 doris definition of remission in sle: final recommendations from an international task force. Lupus science & medicine2021;8: e000538.
30.
YenJCAbrahamowiczMDobkinPL, et al.Determinants of discordance between patients and physicians in their assessment of lupus disease activity. J Rheumatol2003; 30: 1967–1976.
31.
LeongKPChongEYKongKO, et al.Discordant assessment of lupus activity between patients and their physicians: the singapore experience. Lupus2010; 19: 100–106.
32.
PetriM. Disease activity assessment in sle: do we have the right instruments?Ann Rheum Dis2007; 66(Suppl 3): iii61–iii64.
33.
WardMMMarxASBarryNN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol2000; 27: 664–670.
34.
UribeAGVilaLMMcGwinGJr, et al.The systemic lupus activity measure-revised, the mexican systemic lupus erythematosus disease activity index (sledai), and a modified sledai-2k are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol2004; 31: 1934–1940.
35.
GolderVOoiJJYAntonyAS, et al.Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus2018; 27: 501–506.
36.
MozaffarianNLoboscoSLuP, et al.Satisfaction with control of systemic lupus erythematosus and lupus nephritis: physician and patient perspectives. Patient Prefer Adherence2016; 10: 2051–2061.
37.
GoligherECPouchotJBrantR, et al.Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus. J Rheumatol2008; 35: 635–642.
38.
YenJCNevilleCFortinPR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus1999; 8: 660–670.
39.
NevilleCClarkeAEJosephL, et al.Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J Rheumatol2000; 27: 675–679.
40.
ElefanteETaniCStagnaroC, et al.Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus. Arthritis Res Ther2020; 22: 241.
41.
HochbergMC. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
42.
ArgilesJMAnkerSDEvansWJ, et al.Consensus on cachexia definitions. J Am Med Dir Assoc2010; 11: 229–230.
43.
SullivanDHJohnsonLEBoppMM, et al.Prognostic significance of monthly weight fluctuations among older nursing home residents. J Gerontol A Biol Sci Med Sci2004; 59: M633–M639.
44.
BarbackiAPetriMAvina-ZubietaA, et al.Fatigue measurements in systemic lupus erythematosus. J Rheumatol2019; 46: 1470–1477.
45.
ToumaZUrowitzMBGladmanDD. Sledai-2k for a 30-day window. Lupus2010; 19: 49–51.
46.
PetriMKimMYKalunianKC, et al.Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558.
47.
ChallaDNVCrowsonCSDavisJM3rd. The patient global assessment of disease activity in rheumatoid arthritis: identification of underlying latent factors. Rheumatol Ther2017; 4: 201–208.
48.
BlandJMAltmanDG. Statistics notes: calculating correlation coefficients with repeated observations: part 1—correlation within subjects. BMJ1995; 310: 446.
49.
McCormickNMarraCASadatsafaviM, et al.Excess productivity costs of systemic lupus erythematosus, systemic sclerosis, and sjogren's syndrome: a general population-based study. Arthritis Care Res2019; 71: 142–154.
50.
Reategui-SokolovaCGamboa-CardenasRVMedinaM, et al.Health-related quality of life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: data from the almenara lupus cohort. Lupus2021; 30: 2157–2161.
51.
CleanthousSStrzokSHaierB, et al.The patient experience of fatigue in systemic lupus erythematosus: a conceptual model. Rheumatol Ther2022; 9: 95–108.
52.
MonahanRCBeaart-van de VoordeLJEikenboomJ, et al.Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. Lupus2021; 30: 1124–1132.
53.
GarabajiuMSadovici-BobeicaVMazur-NicoriciL, et al. SAT0296 relationship between disease activity index scores and subjective assessments in early systemic lupus erythematosus. Ann Rheum Dis2017; 76: 884–885.
54.
NasaYYokokawaNTakahashiH, et al.Ab0641 correlation between physicians and patients in the assessment of disease activity in systemic lupus erythematosus. Ann Rheum Dis2018; 77: 1467.
55.
KatzPPedroSMichaudK. Performance of the patient-reported outcomes measurement information system 29-item profile in rheumatoid arthritis, osteoarthritis, fibromyalgia, and systemic lupus erythematosus. Arthritis Care Res2017; 69: 1312–1321.
